de Vries NA - Search Results

1

Tumor microvasculature supports proliferation and expansion of glioma-propagating cells.

Borovski T, Verhoeff JJ, ten Cate R, Cameron K, de Vries NA, van Tellingen O, Richel DJ, van Furth WR, Medema JP, Sprick MR. Borovski T, et al. Among authors: de vries na. Int J Cancer. 2009 Sep 1;125(5):1222-30. doi: 10.1002/ijc.24408. Int J Cancer. 2009. PMID: 19431144 Free article.

2

High-grade glioma mouse models and their applicability for preclinical testing.

de Vries NA, Beijnen JH, van Tellingen O. de Vries NA, et al. Cancer Treat Rev. 2009 Dec;35(8):714-23. doi: 10.1016/j.ctrv.2009.08.011. Epub 2009 Sep 19. Cancer Treat Rev. 2009. PMID: 19767151 Review.

3

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O. de Vries NA, et al. Clin Cancer Res. 2007 Nov 1;13(21):6440-9. doi: 10.1158/1078-0432.CCR-07-1335. Clin Cancer Res. 2007. PMID: 17975156

4

Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.

de Vries NA, Bruggeman SW, Hulsman D, de Vries HI, Zevenhoven J, Buckle T, Hamans BC, Leenders WP, Beijnen JH, van Lohuizen M, Berns AJ, van Tellingen O. de Vries NA, et al. Clin Cancer Res. 2010 Jul 1;16(13):3431-41. doi: 10.1158/1078-0432.CCR-09-3414. Epub 2010 May 14. Clin Cancer Res. 2010. PMID: 20472681 Free article.

5

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Marchetti S, et al. Among authors: de vries na. Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250. Mol Cancer Ther. 2008. PMID: 18723475

6

Blood-brain barrier and chemotherapeutic treatment of brain tumors.

de Vries NA, Beijnen JH, Boogerd W, van Tellingen O. de Vries NA, et al. Expert Rev Neurother. 2006 Aug;6(8):1199-209. doi: 10.1586/14737175.6.8.1199. Expert Rev Neurother. 2006. PMID: 16893347 Review.

7

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. de Vries NA, et al. Invest New Drugs. 2012 Apr;30(2):443-9. doi: 10.1007/s10637-010-9569-1. Epub 2010 Oct 21. Invest New Drugs. 2012. PMID: 20963470

8

Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

de Vries NA, Ouwehand M, Buckle T, Beijnen JH, van Tellingen O. de Vries NA, et al. Biomed Chromatogr. 2007 Nov;21(11):1191-200. doi: 10.1002/bmc.874. Biomed Chromatogr. 2007. PMID: 17582233

9

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. de Gooijer MC, et al. Among authors: de vries na. Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28. Neoplasia. 2018. PMID: 29852323 Free PMC article.

10

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

de Vries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, Blom M, van Tellingen O, Jonkers J, van Lohuizen M. de Vries NA, et al. Cell Rep. 2015 Jan 20;10(3):383-397. doi: 10.1016/j.celrep.2014.12.028. Epub 2015 Jan 15. Cell Rep. 2015. PMID: 25600873 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page